Boule Diagnostics awarded contract in USA
Via its US subsidiary, Boule Diagnostics has signed an agreement with Novant Health Systems in the United States, as the primary vendor for three part differential hematology systems. Novant Health System is a highly reputable not-for-profit integrated network of physician clinics, outpatient centers and hospitals in the states of North Carolina, Virginia, South Carolina and Georgia. Novant Health Systems has a total of 15 hospitals and more than 530 doctor’s clinics. Boule estimates that the agreement covers approximately forty hematology systems, including equipment, consumables, service and support through December 31, 2019. Instruments will start to be delivered at the end of the year.
“This agreement strengthens our position on the US market, which is great news for Boule as the US is the world’s largest market by value and where quality and performance really count. We feel this has been instrumental in our being chosen as a supplier, particularly as our systems were not the lowest priced systems. Further proof that our focus on products in the premium segment is spot on,” says Ernst Westman, President and CEO, Boule Diagnostics.
For more information, please contact:
Ernst Westman, CEO and president, Boule Diagnostics AB, tel +46 708-60 88 63
About Boule Diagnostics AB
Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for hematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary hematology. The group is comprised of operating subsidiaries in Sweden, the US and China. The Boule Diagnostics share is traded on NASDAQ Nordic since 2011. www.boule.se
The information in this press release is such that Boule Diagnostics AB must disclose it in accordance with the Securities Market Act and/or the Financial Instruments Trading. The information was submitted for publication in Swedish at 8:45 am (CET), August 26, 2016.
Latest news
-
Boule Diagnostics Interim Report Q3 2025 24 Oct, 2025
-
Boule Diagnostics delårsrapport Q3 2025 24 Oct, 2025
-
BOULE DIAGNOSTICS – INBJUDAN TILL PRESENTATION AV Q3 2025 20 Oct, 2025
-
Boule Diagnostics – Invitation to presentation of the interim report Q3 2025 20 Oct, 2025
-
Boule Diagnostics CFO lämnar för ny möjlighet 13 Oct, 2025
-
Boule Diagnostics Announces CFO Departure for New Opportunity 13 Oct, 2025
-
Boule Diagnostics delårsrapport Q2 2025 18 Jul, 2025
-
Boule Diagnostics Interim Report Q2 2025 18 Jul, 2025